# Pulsed Field Ablation for Atrial Fibrillation: Contemporary Clinical Evidence and Real-World Experience in Redo Ablation

**Authors:** Ioanna Koniari, Eleni Artopoulou, Scott Gall, Gavin S. Chu, Rafail Koros, Maria Bozika, Kassiani-Maria Nastouli, Georgios Leventopoulos, Shajil Chalil, Aruna Arujuna

PMC · DOI: 10.3390/jcm15041647 · 2026-02-22

## TL;DR

Pulsed field ablation is a new technique for treating atrial fibrillation that may reduce risks compared to traditional methods.

## Contribution

This paper reviews contemporary clinical evidence and real-world experience of pulsed field ablation for redo atrial fibrillation ablation.

## Key findings

- Pulsed field ablation may prevent atrial fibrillation recurrence with fewer complications.
- Pulsed field ablation selectively affects cardiomyocyte membranes with minimal damage to surrounding tissues.
- Clinical studies suggest pulsed field ablation is a promising alternative to thermal ablation techniques.

## Abstract

Atrial fibrillation (AF) is the most common prevalent sustained arrhythmia and is associated with stroke, heart failure, and impaired health-related quality of life. Due to the complexity of the initiation and the persistence of AF, the pulmonary vein isolation (PVI) using thermal or laser energy is the most commonly applied ablation strategy. However, these thermal ablation modalities have several limitations, including a substantial risk of AF recurrence and collateral damage to tissues adjacent to the heart. Pulsed field ablation (PFA) is a novel non-thermal ablation technique in which high-voltage electric fields deliver short pulses, selectively affecting cardiomyocyte cell membranes. PFA has the potential to create myocardial lesions with minimal harm to non-cardiac tissues. Clinical studies have evaluated the safety and efficacy of PFA, examining its ability to prevent AF recurrence and its impact on surrounding structures, often in comparison with conventional PVI approaches. In this review, PFA clinical studies are discussed as well as our experience with the PFA use for redo atrial fibrillation ablation cases.

## Linked entities

- **Diseases:** Atrial Fibrillation (MONDO:0004981), stroke (MONDO:0005098), heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** CS (citrate synthase) [NCBI Gene 1431]
- **Diseases:** esophageal injury (MESH:D004941), stroke (MESH:D020521), phrenic nerve paralysis (MESH:D015840), cardiomyopathy (MESH:D009202), cavotricuspid isthmus block (MESH:D006327), myocardial lesions (MESH:D009059), arrhythmia (MESH:D001145), tachycardia (MESH:D013610), edema (MESH:D004487), PFA (MESH:D007922), esophageal, phrenic, or PV injury (MESH:D055370), AF.PVI (MESH:C538261), lesions on pulmonary veins (MESH:D008171), Paroxysmal (MESH:D002819), cerebral lesions (MESH:D002539), flutter (MESH:D054141), injury to (MESH:D014947), cardiac tamponade (MESH:D002305), PV (MESH:D000071078), thromboembolism (MESH:D013923), phrenic nerve lesion (MESH:D020426), HF (MESH:D006333), IMPULSE (MESH:D007174), mucosal injury (MESH:D052016), atrio-esophageal fistula (MESH:D004937), AF (MESH:D001281), esophageal lesions (MESH:D004935), phrenic nerve injury (MESH:D000080902), brain lesions (MESH:D001927), atrial tachycardias (MESH:D013617), atrial flutter (MESH:D001282)
- **Chemicals:** adenosine (MESH:D000241), CS (MESH:D002586), amiodarone (MESH:D000638), gadolinium (MESH:D005682), PFA (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941725/full.md

---
Source: https://tomesphere.com/paper/PMC12941725